2. Amyotrophic lateral sclerosis Clinical trials / Disease details
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05407324 (ClinicalTrials.gov) | November 15, 2022 | 2/6/2022 | Dazucorilant in Patients With Amyotrophic Lateral Sclerosis | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of CORT113176 (Dazucorilant) in Patients With Amyotrophic Lateral Sclerosis (DAZALS) | Amyotrophic Lateral Sclerosis | Drug: Dazucorilant 300 mg;Drug: Dazucorilant 150 mg;Other: Placebo | Corcept Therapeutics | NULL | Recruiting | 18 Years | N/A | All | 198 | Phase 2 | Belgium;France;Netherlands;Poland |